EP Patent

EP2955183A1 — Cdk inhibitors

Assigned to G1 Therapeutics Inc · Expires 2015-12-16 · 10y expired

What this patent protects

Compounds of formulae I or II and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

USPTO Abstract

Compounds of formulae I or II and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number
EP2955183A1
Jurisdiction
EP
Classification
—
Expires
2015-12-16
Drug substance claim
No
Drug product claim
No
Assignee
G1 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.